Nasdaq · Healthcare
Sol-Gel Technologies Ltd. (SLGL)
As-reported financials and recent SEC filings for Sol-Gel Technologies Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$19.4M
Net income
$-6.1M
Net margin
-31.6%
Diluted EPS
$-2.19
ROE
-26.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $19.4M | $11.5M | $1.6M | $3.9M | $31.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $-7.5M | $-12.0M | $-29.3M | $-16.2M | $3.0M |
| Net income | $-6.1M | $-10.6M | $-27.2M | $-14.9M | $3.2M |
| Diluted EPS | $-2.19 | $-3.79 | $-10.01 | $-5.85 | $1.26 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →SCHEDULE 13G/A2026-06-09
View on EDGAR →6-K2026-05-28
View on EDGAR →42026-05-22
View on EDGAR →42026-05-14
View on EDGAR →SCHEDULE 13G/A2026-05-06
View on EDGAR →SCHEDULE 13D/A2026-04-15
View on EDGAR →SCHEDULE 13G2026-03-31
View on EDGAR →Largest Healthcare peers
Go deeper on SLGL
Search Sol-Gel Technologies Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.